Literature DB >> 15852199

Prevention of postmenopausal bone loss and treatment of osteoporosis.

Michael Kleerekoper1.   

Abstract

Osteoporosis is now recognized as an increasingly prevalent disorder throughout the world. Fragility fractures and their subsequent short- and long-term complications are the adverse outcomes of this disease that is essentially silent until fractures occur. Given that the presence of one fragility fracture is an important predictor of the risk of subsequent fractures, prevention of the first fracture is critical whenever possible. Two key elements in fracture prevention that are discussed in this article are the attainment of optimal peak bone mass and the prevention of bone loss at menopause, with the major focus on the prevention of postmenopausal bone loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852199     DOI: 10.1055/s-2005-869481

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  3 in total

Review 1.  Immune modulation by estrogens: role in CNS HIV-1 infection.

Authors:  Melinda E Wilson; Filomena O Dimayuga; Janelle L Reed; Thomas E Curry; Carol F Anderson; Avindra Nath; Annadora J Bruce-Keller
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 2.  Chronic kidney disease and bone fracture: a growing concern.

Authors:  Thomas L Nickolas; Mary B Leonard; Elizabeth Shane
Journal:  Kidney Int       Date:  2008-06-18       Impact factor: 10.612

3.  Case reports: two femoral insufficiency fractures after long-term alendronate therapy.

Authors:  Arkan S Sayed-Noor; Göran O Sjödén
Journal:  Clin Orthop Relat Res       Date:  2009-02-06       Impact factor: 4.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.